BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

  title={BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases},
  author={Bai Lu and Guhan Nagappan and Xiaoming Guan and Pradeep J. Nathan and Paul B. Wren},
  journal={Nature Reviews Neuroscience},
Increasing evidence suggests that synaptic dysfunction is a key pathophysiological hallmark in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of brain-derived neurotrophic factor (BDNF) in synaptic plasticity and synaptogenesis, the impact of the BDNF Val66Met polymorphism in Alzheimer's disease-relevant endophenotypes — including episodic memory and hippocampal volume — and the technological progress in measuring synaptic changes in humans all pave the way… 
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential
An overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling is presented and the potential of BDNF-targeting therapeutics for AD is discussed.
Possible protective action of neurotrophic factors and natural compounds against common neurodegenerative diseases
Small natural compounds such as flavonoids that successfully increase activation of the BDNF system are introduced and their beneficial effects against neurodegeneration are discussed.
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy
E enlightening the detailed biological ability and complicated mechanisms of action of BDNF in the context of AD would provide a future BDNF-related remedy for AD, such as increment in the production or release of endogenous BDNF by some drugs or BDNF mimics.
Towards universal therapeutics for memory disorders.
Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease
  • J. Keifer
  • Biology, Psychology
    Journal of neuroscience research
  • 2022
The aim is to draw attention to the need for increasing patient‐directed clinical studies to test the possible benefits of increasing levels of neurotrophins, specifically BDNF, to treat brain disorders.
Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease
P021 is a neurogenic and neurotrophic compound which enhances dentate gyrus neurogenesis and memory processes via inhibiting leukemia inhibitory factor (LIF) signaling pathway and increasing brain-derived neurotrophic factor (BDNF) expression and has emerged as a highly promising compound for AD drug development.


Alzheimer's disease: synaptic dysfunction and Aβ
The evidence that non-fibrillar soluble forms of Aβ are mediators of synaptic compromise is reviewed and the possible mechanisms of A β synaptotoxicity and potential targets for therapeutic intervention are discussed.
Synaptic dysfunction in Parkinson's disease.
In neuronal circuits, memory storage depends on activity-dependent modifications in synaptic efficacy, such as LTD (long-term depression) and LTP (long-term potentiation), the two main forms of
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
Broad neuroprotective effects of entorhinal brain-derived neurotrophic factor administration in several animal models of Alzheimer's disease are shown, with extension of therapeutic benefits into the degenerating hippocampus.
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Impairments in functional synaptic plasticity may underlie some of the cognitive deficits in these mice and, possibly, in Alzheimer's patients.
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
The current understanding and future directions in BDNF-related research in the central nervous system are reviewed, with an emphasis on the possible therapeutic application of BDNF in modifying fundamental processes underlying neural disease.
Hippocampal synaptic plasticity in Alzheimer’s disease: what have we learned so far from transgenic models?
Transgenic (Tg) mouse models of Alzheimer’s disease are used to investigate mechanisms underlying disease pathology and identify therapeutic strategies, and common synaptic alterations in the various models that might underlie the memory deficits observed in these mice were searched for.
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.
It is proposed that these compounds constitute a novel group of tools for the study of TrkB signaling and may provide leads for developing new therapeutic agents for neurodegenerative diseases.
The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease.
The novel findings provide convergent evidence in vivo for a BDNF genetic mechanism of susceptibility in an intermediate phenotype related to AD by examining cortical thickness, fractional anisotropy of white matter tracts, and episodic memory performance.